Papers/PMID:40180416
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.
BMJ open2025The record
6 findings · 1 compound · 6 endpoints · 6 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
6 findings
lipoic acid — no detected effect on HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
lipoic acid — no detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
lipoic acid — no detected effect on total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
lipoic acid — no detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
lipoic acid — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
lipoic acid — no detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink